News & Events about Vectivbio Holding Ag.
Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and womenBASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel ...
Globe Newswire
4 months ago
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive ...
Globe Newswire
5 months ago
BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held...
Globe Newswire
9 months ago
Combined Gross Proceeds from Public Offering and Private Sale Total $50 MillionBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, ...
Globe Newswire
9 months ago
Interim proof-of-concept data anticipated from STARGAZE in H1 2023 First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease Second clinical indication under evaluation for apraglutide, demonstrating broad potential of this next generation GLP-2 analog ...